ASX ANNOUNCEMENT | 20 November 2026

# Explanatory Note to Appendix 3Z

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, advises that the attached Appendix 3Z (Final Director's Interest Notice) for former director Ms Melanie Leydin is being lodged after the time required under ASX Listing Rule 3.19A.3.

Ms Leydin ceased to be a director of the Company on 30 October 2026. The Appendix 3Z was not lodged within the prescribed timeframe due to an administrative oversight following her resignation.

The Company notes that, at the date of her resignation, Ms Leydin did not hold any securities in the Company and had no direct interests in any contracts to which the Company was a party.

The Company considers that it has in place appropriate arrangements under ASX Listing Rule 3.19B to ensure compliance with its disclosure obligations regarding directors' interests. These arrangements include ongoing communication between directors, the Company Secretary and relevant administrative personnel, together with procedures requiring the prompt notification of changes to directors' interests and offices held.

In this instance, the Company's arrangements did not operate effectively, as the requirement to lodge an Appendix 3Z following Ms Leydin's resignation was inadvertently overlooked during the director cessation process. The Company has reviewed and reinforced its internal compliance procedures to help ensure that all future notices required under ASX Listing Rule 3.19A.3 are lodged within the prescribed timeframe.

The Company remains committed to complying with its obligations under the ASX Listing Rules and considers the above measures appropriate to minimise the risk of a recurrence.

## Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

## Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via Investor Hub. Register at investor.imagionbiosystems.com.

###

## About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic

certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com.

**Executive Chairman Contact Details**
Bob Proulx
investor@imagionbio.com
AU: +61 3 9692 7222

**Media Enquiries & Investor Relations**
Erich Boileau, Boileau & Co.
imagionbio@boileau.co
US : +1 (616) 786-4461

*Rule 3.19A.3*

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

| | |
|---|---|
| **Name of entity** | Imagion Biosystems Limited |
| **ABN** | 42 616 305 027 |

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of director** | Ms Melanie Leydin |
| **Date of last notice** | 31 July 2024 |
| **Date that director ceased to be director** | 30 October 2026 |

**Part 1 – Director's relevant interests in securities of which the director is the registered holder**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| **Number & class of securities** |
|---|
| Nil |

+ See chapter 19 for defined terms.

11/3/2002

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

| **Name of holder & nature of interest**<br>Note: Provide details of the circumstances giving rise to the relevant interest | **Number & class of securities**<br><br>Nil |
|---|---|

### Part 3 – Director's interests in contracts

| | |
|---|---|
| **Detail of contract** | Nil |
| **Nature of interest** | |
| **Name of registered holder (if issued securities)** | |
| **No. and class of securities to which interest relates** | |

+ See chapter 19 for defined terms.